Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Treasury Shares (2020 - 2025)

Heron Therapeutics' Treasury Shares history spans 6 years, with the latest figure at $3.8 million for Q4 2025.

  • For Q4 2025, Treasury Shares rose 91.77% year-over-year to $3.8 million; the TTM value through Dec 2025 reached $3.8 million, up 91.77%, while the annual FY2025 figure was $3.8 million, 91.77% up from the prior year.
  • Treasury Shares reached $3.8 million in Q4 2025 per HRTX's latest filing, down from $4.0 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $1.8 billion in Q3 2023 to a low of $570000.0 in Q1 2021.
  • Average Treasury Shares over 5 years is $91.6 million, with a median of $2.6 million recorded in 2022.
  • Peak YoY movement for Treasury Shares: skyrocketed 63301.53% in 2023, then crashed 99.91% in 2024.
  • A 5-year view of Treasury Shares shows it stood at $2.8 million in 2021, then increased by 12.99% to $3.2 million in 2022, then plummeted by 55.64% to $1.4 million in 2023, then surged by 41.0% to $2.0 million in 2024, then skyrocketed by 91.77% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Treasury Shares are $3.8 million (Q4 2025), $4.0 million (Q3 2025), and $4.1 million (Q2 2025).